US Patent 11015211 Cardiac cell reprogramming with myocardin and ASCL1
Patent 11015211 was granted and assigned to Tenaya Therapeutics on May, 2021 by the United States Patent and Trademark Office.
Name
# Contributions
Last Contribution
Find more entities like US Patent 11015211 Cardiac cell reprogramming with myocardin and ASCL1
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
By using this site, you agree to our Terms of Service.